Bleeding Clinical Trial
Official title:
Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting
Verified date | October 2019 |
Source | United Health Products, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to assess efficacy and safety of HemoStyp as an adjunct for management of secondary hemostasis in the operative setting.
Status | Completed |
Enrollment | 236 |
Est. completion date | September 12, 2019 |
Est. primary completion date | August 5, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years and older |
Eligibility | Inclusion Criteria: 1. Elective procedure (non-laparoscopic thoracic, cardiac, abdominal, or vascular surgery); 2. At time of surgery has mild to moderate soft tissue, vascular or parenchymal bleeding present at target bleeding site after primary standard conventional surgical hemostatic methods are proven to be ineffective or impractical; 3. Ages: Pediatric subjects 2 years to 17 years of age and adult subjects 18 years of age or older; and 4. Subjects or parent or legal guardian of the subject who are willing and able to sign consent. Exclusion Criteria: 1. Physical or psychological condition which would impair study participation; 2. Indications for emergency surgery; 3. Pre-operative laboratory findings of a hematologic disorder; 4. Subjects with history of moderate to severe allergies; 5. Subjects undergoing minimally invasive laparoscopic surgery; 6. Subjects who will require platelet or fresh frozen plasma transfusion during surgery; 7. Subjects who are pregnant or breast-feeding at the time of surgery; or 8. Subjects on P2Y12 platelet inhibitor (Plavix) less than 5 days prior to surgery, warfarin or Xa inhibitors not withheld per standard protocols for the management of anticoagulants pre-operatively. |
Country | Name | City | State |
---|---|---|---|
United States | Raymond Schaerf | Burbank | California |
Lead Sponsor | Collaborator |
---|---|
United Health Products, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The Time to Hemostasis Measured From Start of Study Treatment to the Achievement of Hemostasis at the Target Bleeding Site (TBS), or to the End of the 10-minute Observation Period. | The time to hemostasis was measured from start of study treatment to the achievement of hemostasis at the target bleeding site (TBS), or to the end of the 10-minute observation period. The time to hemostasis was considered as censored at the end of the 10-minute observation period. Time to hemostasis was quantified in minutes according to its nominal time point. When re-bleeding occurred, and the cessation of bleeding is again achieved at a later time point, the effective time to hemostasis was the latter time point. The time to hemostasis was the time from start of study treatment to that last effective hemostatic time point. | 10 minutes | |
Secondary | Percentage of Subjects Achieving Hemostasis Between 2 Minutes and 10 Minutes | Percentage of subjects achieving hemostasis at the target bleeding site at 2 minutes, 5 minutes and 10 minutes following the start of study treatment. | Between 2 minutes and 10 minutes | |
Secondary | Rate of Subjects Achieving Intraoperative Hemostasis at the Target Bleeding Site | Percentage of subjects with intraoperative hemostasis at the target bleeding site during the intraoperative period. The intraoperative period started when the first cut was made to the patient and ended when the operative field was closed and dressed. | Intraoperative period | |
Secondary | Rate of Subjects With Intraoperative Re-bleeding From the Target Bleeding Site | Percentage of subjects with intraoperative re-bleeding from the target bleeding site post hemostasis | Intraoperative period post hemostasis | |
Secondary | Rate of Subjects Requiring Surgical Re-exploration up to 30 Days After Surgery for Re-bleeding From the Target Bleeding Site | Postoperative re-bleeding from the target bleeding site requiring surgical re exploration up to 30 days after surgery. | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT04058223 -
Comparison of the Short-term Outcomes of Using DST and PPH Staplers in the Treatment of Grade III and IV Hemorrhoids
|
||
Completed |
NCT05669313 -
The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
|
||
Completed |
NCT04590898 -
Peri-device Leakage Closure After LAAO
|
||
Active, not recruiting |
NCT05563883 -
Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
|
||
Not yet recruiting |
NCT04537533 -
Tranexamic Acid Infusion in Low Dose Versus in High Dose for Reducing Blood Loss in Radical Cystectomy Operations
|
Phase 4 | |
Withdrawn |
NCT02851940 -
Pain and Bleeding Following Hypertonic Saline Sclerotherapy Compared to Brand Ligation for Symptomatic Hemorrhoids
|
N/A | |
Completed |
NCT02722720 -
Carotid Arteries Stenting Complications: Transradial Approach Versus Transfemoral
|
N/A | |
Recruiting |
NCT02279186 -
Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section
|
Phase 4 | |
Active, not recruiting |
NCT02244853 -
Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease
|
N/A | |
Completed |
NCT02092415 -
Assessment of Limb Perfusion During Junctional Tourniquet
|
N/A | |
Completed |
NCT02245854 -
Efficacy and Safety of a New Polypectomy Snare for Cold-polypectomy for Small Colorectal Polyps
|
N/A | |
Completed |
NCT02980497 -
Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study
|
N/A | |
Not yet recruiting |
NCT01438736 -
Is Cerazette Use Before Nexplanon Insertion Predictive for Bleeding Pattern?
|
Phase 4 | |
Completed |
NCT00515541 -
Lovaza's Effect on the Activation of Platelets
|
Phase 2 | |
Completed |
NCT00143715 -
Oral Vitamin K for Warfarin Associated Coagulopathy
|
Phase 3 | |
Terminated |
NCT03954314 -
DEPOSITION - Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery
|
Phase 3 | |
Recruiting |
NCT05945680 -
Tranexamic Acid in Breast Esthetic Surgery.
|
Phase 4 | |
Recruiting |
NCT03783182 -
Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy
|
Phase 4 | |
Not yet recruiting |
NCT05464394 -
Peroperative Administration of Tranexamic Acid in Roux-en-Y Gastric Bypass and One-anastomosis Gastric Bypass
|
Phase 3 |